The ApoB Blind Spot: How ACC/AHA Guidelines Underemphasize the Most Important Lipid Risk Marker

This editorial critiques the 2018 ACC/AHA cholesterol guidelines for their treatment of apolipoprotein B — specifically their failure to place ApoB at the center of lipid risk assessment despite a compelling and accumulating evidence base.

Sniderman argues that the guidelines acknowledge ApoB as superior to LDL-C and non-HDL-C in specific clinical contexts — including discordance situations, patients with elevated triglycerides, metabolic syndrome, diabetes, and insulin resistance — but relegate it to a secondary role rather than making it the primary therapeutic target. The editorial reviews the mechanistic and epidemiological basis for ApoB superiority, including concordance analyses from large trials showing that when LDL-C and ApoB disagree, ApoB better predicts cardiovascular outcomes.

The clinical implication is that guidelines are lagging evidence in a way that has real consequences. Patients with elevated ApoB but apparently controlled LDL-C are being systematically undertreated. The guideline structure — which positions LDL-C as the primary target and ApoB as an optional confirmatory measure — inverts the logical relationship between a direct particle-count measure and a derived cholesterol-content measure.

This editorial anticipates the direction of subsequent guideline revisions, which have moved incrementally toward recognizing ApoB as a preferred target in certain patient populations, particularly those with metabolic syndrome and high-triglyceride states.

We rate the evidence limited. An evidence-grounded editorial by a leading authority challenging the ApoB treatment hierarchy in ACC/AHA guidelines — influential in the ongoing professional debate about adopting ApoB as the primary lipid risk marker.